Johannes Zanzinger - Profile and Investment Details

Investor Profile

Johannes Zanzinger is a Venture Capital, Corporate Venture Capital, Investor based in Ulm, Baden-Württemberg, Germany with a diverse investment portfolio that includes companies such as Aignostics, T3 Pharmaceuticals, Dopavision, Topas Therapeutics, Actym, eTheRNA immunotherapies, STAT-Dx, Rinri Therapeutics, Rigontec, Hookipa Pharma, Tacalyx, NBE-Therapeutics, Aelin Therapeutics, Metabomed Ltd., Okairos, ImCheck Therapeutics, Wellth, T-knife, Brainomix, Centauri Therapeutics Limited, Acousia Therapeutics, Rgenta Therapeutics, DiogenX, Cardior Pharmaceuticals, HepaRegeniX GmbH, Delonix Bioworks, Bodyport, Ruipeng Pet Healthcare, Boehringer IngelheimMetabomed, ArmaGen Technologies, Rewind Therapeutics, HepaRegeniX, Perfood, Eyevensys, Promethera Biosciences, Sentien Biotechnologies, Amal Therapeutics, Vira Therapeutics, OncoMyx Therapeutics, Libra Therapeutics, Abalos Therapeutics, AgomAb Therapeutics, Centauri Therapeutics, . Over time, Johannes Zanzinger has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Johannes Zanzinger is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Hospitals, Data Science, Human Computer Interaction, Online Education, Wellness, Women Founded, Digital Media, Career Management, Energy, Chemical, Life Science, Engineering, Health Technology, Education, Artificial Intelligence (AI), Bioinformatics, Software, Biotechnology, Business Management, Cosmetics, Communication Technology, Innovation, Digital Transformation, High Tech, Computer Science, Digital Learning, Consulting, Sustainable Energy, Colleges, Technology Transfer, Utilities, High-Performance Computing, Health Diagnostics, Nanotechnology, Higher Education, Medical, Information Technology, B2B, Therapeutics, Advanced Materials, Machine Learning, Personal Health, Quantum Computing, Material Science, Pharmaceuticals may find it worthwhile to explore potential connections with Johannes Zanzinger, as their portfolio suggests a familiarity and interest in this area.

Understanding Johannes Zanzinger’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.